+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Orphan Drug"

From
Primary Ciliary Dyskinesia (PCD) Market Report 2026 - Product Thumbnail Image

Primary Ciliary Dyskinesia (PCD) Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Contract Research Organization Market - Global Forecast 2026-2032 - Product Thumbnail Image

Contract Research Organization Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 191 Pages
  • Global
From
From
From
From
Bacteriophage Therapy Market - Global Strategic Business Report - Product Thumbnail Image

Bacteriophage Therapy Market - Global Strategic Business Report

  • Report
  • September 2026
  • 494 Pages
  • Global
From
Plasma-Derived Medicines Market - Global Strategic Business Report - Product Thumbnail Image

Plasma-Derived Medicines Market - Global Strategic Business Report

  • Report
  • September 2026
  • 391 Pages
  • Global
From
Oligonucleotides - Competitive Landscape, 2026 - Product Thumbnail Image

Oligonucleotides - Competitive Landscape, 2026

  • Report
  • January 2026
  • 450 Pages
  • Global
From
From
From
From
From
From
From
From
From
Loading Indicator

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more